Cost-effectiveness of a single dose of the adjuvanted RSVPreF3 vaccine for the prevention of respiratory syncytial virus (RSV) among patients with chronic obstructive pulmonary disease in Italy

Key Points

• This research evaluates the cost-effectiveness of the RSVPreF3 vaccine for preventing RSV in COPD patients aged 60-74 in Italy.
• Cost-effectiveness analysis conducted over a five-year period
• Population included COPD patients aged 60-74
• Evaluation of healthcare costs related to RSV disease burden
• Single dose of RSVPreF3 vaccine is cost-effective
• Potential reduction in RSV-related healthcare costs and disease burden
• Benefits observed over a five-year horizon